Prevalence of RET/PTC expression in papillary thyroid carcinoma and its correlation with prognostic factors in a north Indian population

被引:5
|
作者
Mishra, A. [1 ]
Agrawal, V [2 ]
Krishnani, N. [2 ]
Mishra, S. K. [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrine Surg, Lucknow 226014, Uttar Pradesh, India
[2] Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow 226014, Uttar Pradesh, India
关键词
DTC; oncogene; rearranged during transfection protein; ONCOGENE ACTIVATION; PROTEIN EXPRESSION; GENE REARRANGEMENTS; RET; TUMORS; CHILDREN; LESIONS; SEARCH; CANCER;
D O I
10.4103/0022-3859.57390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The prevalence of Rearranged during Transfection/ Papillary Thyroid Carcinoma (RET/PTC) rearrangement in papillary thyroid carcinoma (PTC) varies in different geographic regions and its prognostic significance remains unclear. Aim: The aim of this study was to recognize the prevalence of RET/PTC expression in PTC from the endemically iodine-deficient region in Northern India and to correlate the expression with the clinicopathologic prognostic factors. Settings and Design: Retrospective. Archival tissue used. Materials and Methods: Immunohistochemistry was performed to look for activated RET protein expression in 50 cases of PTC. No patient had any history of prior irradiation. Statistical Analysis Used: Chi-square method, Student t test, and binary regression method. A P value of <.05 was considered significant for all the tests. Results: The prevalence of RET expression was 44%. Twenty-six (52%) cases showed RET immunoreactivity in histiocytes. Immunoreactivity was the highest in the classic variant of PTC (47.5%), followed by tumors with poorly differentiated areas (25%) and follicular variant (16.7%). RET expression was more prevalent in young patients (45.5 vs. 35.3%), females (43.3 vs. 40.0%), small tumors (33.3 vs. 26.7%), multicentric tumors (36.8 vs. 33.3%), tumors with extrathyroidal invasion (38.9 vs. 32.4%), and regional lymphadenopathy (55.2 vs. 22.2%), while it was less in cases with distant metastases (20 vs. 43.9%). There was no significant correlation of immunoreactivity with any prognostic factor. However, when the cases having immunoreactivity within histiocytes (n = 26) and histiocytes + tumor tissue (n = 28) were considered, then the expression was significantly more in cases with lymphadenopathy (P values =.009, in both instances). However, the exact clinical significance of RET/PTC positive histiocytes remained unexplained. Conclusions: Prevalence of RET/PTC in our study was consistent with the reported prevalence from other geographic areas. There was no significant correlation with the clinicopathologic factors. However, uniform techniques of detection and large international collaborative studies could clear the uncertainties regarding the prognostic importance of RET/PTC.
引用
下载
收藏
页码:171 / 175
页数:5
相关论文
共 50 条
  • [31] Expression of Ret/PTC1, -2, -3, -Δ3 and -4 in German papillary thyroid carcinoma
    Mayr, B
    Pötter, E
    Goretzki, P
    Rüschoff, J
    Dietmaier, W
    Hoang-Vu, C
    Dralle, H
    Brabant, G
    BRITISH JOURNAL OF CANCER, 1998, 77 (06) : 903 - 906
  • [32] Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma
    Zafon, C.
    Obiols, G.
    Castellvi, J.
    Tallada, N.
    Baena, J. A.
    Simo, R.
    Mesa, J.
    HISTOPATHOLOGY, 2007, 50 (02) : 225 - 231
  • [33] Warthin-like tumour of the thyroid gland: RET/PTC expression indicates it is a variant of papillary carcinoma
    D'antonio, A
    De Chiara, A
    Santoro, M
    Chiappetta, G
    Losito, NS
    HISTOPATHOLOGY, 2000, 36 (06) : 493 - 498
  • [34] Expression of Ret/PTC1, -2, -3, -Δ3 and -4 in German papillary thyroid carcinoma
    B Mayr
    E Pötter
    P Goretzki
    J Rüschoff
    W Dietmaier
    C Hoang-Vu
    H Dralle
    G Brabant
    British Journal of Cancer, 1998, 77 : 903 - 906
  • [35] RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas -: Authors' response
    Learoyd, DL
    Robinson, BG
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (06): : 2258 - 2258
  • [36] BREAKPOINT CHARACTERIZATION OF THE RET/PTC ONCOGENE IN HUMAN PAPILLARY THYROID-CARCINOMA
    SMANIK, PA
    FURMINGER, TL
    MAZZAFERRI, EL
    JHIANG, SM
    HUMAN MOLECULAR GENETICS, 1995, 4 (12) : 2313 - 2318
  • [37] Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma
    Basolo, F
    Giannini, R
    Monaco, C
    Melillo, RM
    Carlomagno, F
    Pancrazi, M
    Salvatore, G
    Chiappetta, G
    Pacini, F
    Elisei, R
    Miccoli, P
    Pinchera, A
    Fusco, A
    Santoro, M
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (01): : 247 - 254
  • [38] Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation
    Jeong, Woo-Jin
    Mo, Ji-Hun
    Park, Min Woo
    Choi, Ik Joon
    An, Soo-Youn
    Jeon, Eun-Hee
    Ahn, Soon-Hyun
    CANCER BIOLOGY & THERAPY, 2011, 12 (05) : 458 - 465
  • [39] Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma
    Finn, SP
    Smyth, P
    O'Leary, J
    Sweeney, EC
    Sheils, O
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02): : 938 - 941
  • [40] Expression of MAP kinases in Papillary Thyroid Carcinoma (PTC)
    Saini, M. Lamba
    Weynand, B.
    Rahier, J.
    Mourad, M.
    Hamoir, M.
    Marbaix, E.
    VIRCHOWS ARCHIV, 2014, 465 : S26 - S26